

1 NMDA receptor signalling controls R-type calcium 2 channel levels at the neuronal synapse

3 Oleg O. Glebov^{1,2*}

4

5 ¹ Institute of Neuroregeneration and Neurorehabilitation, Qingdao University, Qingdao
6 266071, Shandong, China.

7 ² Department of Old Age Psychiatry, The Institute of Psychiatry, Psychology &
8 Neuroscience, King's College London, De Crespigny Park, Denmark Hill, London SE5 8AF, UK.

9 E-mail: oleg.glebov@kcl.ac.uk

10

11

12 Abstract

13 **Regulation of extracellular Ca⁺⁺ influx by neuronal activity is a key mechanism**
14 **underlying synaptic plasticity. At the neuronal synapse, activity-dependent Ca⁺⁺ entry**
15 **involves NMDA-type glutamate receptors (NMDARs) and voltage-gated calcium channels**
16 **(VGCCs); the relationship between NMDARs and VGCCs, however, is poorly understood.**
17 **Here, I report that neuronal activity specifically regulates synaptic levels of R-type**
18 **VGCCs through synaptic NMDAR signalling and protein translation. This finding reveals**
19 **a link between two key neuronal signalling pathways, suggesting a feedback mode for**
20 **regulation of Ca⁺⁺ signalling at the synapse.**

21

22 Introduction

23 The calcium (Ca^{++}) ions play a central role in the regulation of the synaptic function in the
24 central nervous system (CNS). Upon arrival of the action potential to the synapse, entry of
25 extracellular Ca^{++} through voltage-gated calcium channels (VGCCs) results in docking of the
26 synaptic vesicles to the presynaptic active zone and the release of the neurotransmitter into the
27 synaptic cleft, resulting in synaptic transmission [1,2]. On the other side of the synapse,
28 depolarization of the membrane by opening of the neurotransmitter receptors opens up VGCCs
29 as well as NMDA-type glutamate receptors (NMDARs), which enable Ca^{++} to enter the
30 dendritic spine. Ca^{++} then triggers a complex cascade of signalling pathways that can relay
31 information as far as the cell nucleus, regulating multiple aspects of cell biology such as gene
32 expression, membrane trafficking and protein turnover [3].

33 NMDARs and VGCCs are the two main sources of Ca^{++} entry into the synapse. VGCCs are
34 complex proteins possessing multiple transmembrane domains, which open up to allow
35 passage of Ca^{++} once the cell membrane has depolarized beyond a certain level [1,4]. On the
36 other hand, NMDA receptors sense both depolarization of the membrane and release of
37 glutamate, which enables them to open and allow for entry of various cations, including Ca^{++}
38 [5,6]. The properties of these channels are therefore quite different. Furthermore, localization of
39 these channels at the synapse also displays notable differences: while NMDARs are specifically
40 located at the postsynaptic dendritic spine, VGCC can be found on both sides of the synapse.

41 Fast high-voltage VGCCs containing a Cav2 subunit (Cav2-VGCCs) are of particular
42 importance to synaptic Ca^{++} signalling, as they specifically localize to the synapse. Amongst
43 the three known types of Cav2-VGCCs, P/Q-type (Cav2.1) and N-type (Cav2.2) VGCCs are
44 found on the presynaptic side [7–10], while R-type (Cav2.3) channels operate on both sides of
45 the synapse [11–13]. Despite the well-established roles for both NMDARs and Cav2-VGCCs,
46 the relationship between their signalling pathways remains poorly understood. Local NMDAR
47 and VGCC signalling can be immediately coupled through the short-term biophysical
48 mechanisms [14,15]. On a timescale of days, chronic levels of neuronal activity engage the
49 mechanisms of homeostatic plasticity to regulate many aspects of synaptic protein composition,
50 including all three types of Cav2-containing VGCCs [10,16]. However, the link between NMDAR
51 activity and synaptic Cav2-VGCCs levels remains unclear, and do the underlying cell biological
52 mechanisms.

53 Materials and Methods

54 Materials

55 Cell culture reagents were from Invitrogen (UK). Anisomycin, MK801 and memantine were from
56 Sigma Aldrich (UK). TTX, NBQX, APV, and gabazine were from Tocris (UK).

57 Below is the list of the antibodies used in this study:

Antigen	Conjugation	Species	Manufacturer	Cat. No.
Cav2.3		Rabbit	Synaptic Systems	135302
PSD95		Mouse	Abcam	13552
Bassoon		Mouse	Abcam	82958
Cav2.1		Rabbit	Synaptic Systems	152103
Cav2.2		Rabbit	Alomone	ACC-002
Rabbit IgG	Cy5	Donkey	Jackson Immuno	711-175-152
Mouse IgG	AlexaFluor488	Goat	Invitrogen	A-11001

58

59 Neuronal culture

60 Dissociated hippocampal neuronal cultures were isolated from rat embryos at day 18 of
61 gestation and grown according to the Brewer method. Culture medium was Neurobasal with
62 GlutaMax and B-27. No anti-mitotic agents or antibiotics were used during culture. All
63 experiments were carried out at 16-21 days in culture. Cells were cultured on 13 mm poly-L-
64 lysine coated round glass coverslips with 1.5 thickness placed into 35 mm Petri dishes, 4
65 coverslips per dish. To minimise variability in culture conditions, each experiment was carried
66 out using the cells from the same dissection and cultured within the same Petri dish. All
67 experimental protocols were performed following the guidelines of the local Research Ethics
68 Committee.

69 Immunostaining and confocal microscopy

70 All steps were performed at room temperature (RT). After treatment, coverslips were fixed with
71 2% (when probing for Psd95) or otherwise 4% para-formaldehyde dissolved in phosphate
72 buffered saline (PBS). Fixation was carried out for 15–20min and was followed by the
73 permeabilization/blocking step. Permeabilization/blocking was carried out in 0.2% Triton-X100
74 dissolved in PBS supplemented with 5% horse serum, for 10 min. All subsequent incubations
75 were carried out in 0.2% Triton-X100 dissolved in PBS supplemented with 5% horse serum. For
76 primary labelling, coverslips were incubated with appropriate primary antibodies for 45-90 min,
77 then washed 4 times in PBS. For secondary labelling, coverslips were incubated with the
78 appropriate secondary antibodies labelled with AlexaFluor-488 and AlexaFluor-647 at a
79 concentration of 0.3 $\mu\text{g}/\text{mL}$ each for 45-90 min. Coverslips were then mounted in Fluoromount-
80 G mounting medium and imaged on a Zeiss LSM710 laser confocal microscope equipped with a
81 standard set of lasers. The imaging system was controlled by ZEN software. Acquisition
82 parameters were as follows: plan-Apochromat 63x/1.4 Oil objective, regions of interest sized
83 1024x1024 pixels (65.8 nm/pixel), 12-bit, speed 7, averaging setting 2. Excitation laser
84 wavelengths were 488 and 633nm. Bandpass filters were set at 500–550nm and 650–750nm
85 for AlexaFluor-488 and AlexaFluor647 respectively. Pinhole size was kept to 1-2 Airy units.
86 Detector gain settings were optimized to ensure appropriate dynamic range, low background
87 and sufficient signal/noise ratio.

88 Image analysis

89 Image analysis was carried out using the ImageJ software package, version 1.42. Non-synaptic
90 regions with high background fluorescence (e.g. cell bodies) were manually excluded from
91 analysis. For identification of synapses, images were semi-automatically thresholded using the
92 “Moments” setting. Individual synapses were then identified automatically using the “Analyze
93 Particles” command. To avoid rare overlap of multiple synapses, only synapses with areas
94 ranging from 0.1 to $2\mu\text{m}^2$ were included in further analysis. Spatial parameters of the identified
95 synapses were then added to the Region of Interest (ROI) Manager. Individual ROIs were then
96 combined into one compound ROI using the “Combine” and “Add” functions of the ROI Manager
97 interface, whereupon quantification of mean signal intensity in each channel was performed
98 using the “Measure” function. Background subtraction was performed as appropriate.

99 Statistical analysis

100 All the experiments were repeated 3 to 5 times, 5 images per condition. For statistical analysis,
101 Prism 6.0c software package (GraphPad Software) was used. Data distributions were assessed
102 for normality using d'Agostino and Pearson omnibus tests. Student's t-test and 1-way ANOVA
103 were used for normally distributed datasets to assess statistical significance; for not normally
104 distributed datasets, Mann-Whitney rank test was used. Dunnett's post-test was used to assess
105 statistical significance of the treatment effects relative to the untreated control samples. Graph
106 plots show mean values and standard error from the mean (SEM).

107 Results&Discussion

108 Blockade of action potential firing by TTX (2uM) for 1 hour caused a significant increase in the
109 Cav2.3 levels within the puncta of a canonical synaptic marker PSD95 (**Fig 1a,b**), although the
110 synaptic level of PSD95 itself was unchanged (**Fig. S1a**). Blockade of inhibitory transmission by
111 a GABA receptor blocker Gabazine (50uM) also increased the synaptic levels of Cav2.3, while
112 moderate depolarization of the neuronal membrane by elevated (15mM) concentration of KCl
113 had no significant effect (**Fig 1a,b**). This indicated that neuronal activity regulated synaptic
114 levels of R-VGCCs.

115 To investigate the mechanism coupling neuronal activity and synaptic R-VGCCs, AMPA-type
116 glutamate receptors, which carry out most of glutamatergic synaptic transmission in
117 hippocampus, were blocked using NBQX (20uM). The observed increase in synaptic Cav2.3
118 plevels resembled that of TTX, suggesting that R-VGCCs leves were reguated by excitatory
119 synaptic transmission (**Fig. 1c**). To further elucidate the signalling mechanism regulating R-
120 VGCCs downstream of synaptic transmission, NMDAR signaling was inibited by a specific
121 blocker APV (50uM). The resulting effect was similar to that of TTX and NBQX, indicating that
122 blockade of NMDARs was sufficient to induce recruitment of R-VGCCs to the synapse.
123 Importantly, treatment with a structurally unrelated NMDAR blocker MK801 (20uM) had the
124 same effect as APV, further confirming involvement of NMDAR signalling in synaptic R-VGCC
125 regulation (**Fig. 1c**).

126 To further confirm synaptic enrichment of Cav2.3, we quantified the Cav2.3 levels in areas
127 labeled by a different synaptic marker Bassoon (Bsn). Treatment with APV or MK801
128 significantly increased Cav2.3 relative to Bsn levels, indicating that the change in the ratio was
129 indeed caused by the specific increase in synaptic levels of Cav2.3 (**Fig. 1d,e**). This conclusion
130 was further supported by an increase in the somatic levels of Cav2.3, suggesting that the levels

131 of R-VGCCs were increased across the cell rather than only at the synapse (Fig). ($p < 0.05$,
132 Mann-Whitney test, **Fig. S1b**).

133 Other types of Cav-2 containing VGCCs, namely N-VGCCs and P/Q-VGCCs, have been shown
134 to slowly accumulate at the synapse over the course of 24-48h upon blockade of activity,
135 consistent with the timescale of homeostatic plasticity [10,16]. To investigate whether their
136 timescale of their recruitment matched that of R-VGCCs, immunostaining for the pore-forming
137 subunits Cav2.1 and Cav2.2 was performed in cultures treated with APV for 1h (**Fig. S1c,d**).
138 Synaptic levels of both Cav2.1 and Cav2.2 were not significantly increased, suggesting that the
139 accumulation of VGCCs at the synapse triggered by the 1h NMDAR blockade is restricted to R-
140 VGCCs and does not affect N-VGCCs and P/Q-VGCCs (**Fig. S1e,f**).

141 Besides synaptic NMDARs, activation of extrasynaptic NMDARs has also been implicated in
142 physiologically and clinically important signalling pathways, including neurotoxicity. To
143 differentiate between these two modes of NMDAR signalling, I took advantage of the
144 pharmacological profile of the drug memantine, which preferentially inhibits extrasynaptic
145 NMDAR in low concentrations [17]. Treatment with low concentrations of memantine (1-10uM)
146 had no effect on Cav2.3 accumulation, whereas a higher concentration (100uM) significantly
147 increased synaptic Cav2.3 (**Fig. 1f**). Therefore, it can be concluded that synaptic rather than
148 extrasynaptic NMDARs signalling regulates synaptic R-VGCCs.

149 A major mechanism for NMDAR-dependent regulation of synaptic composition is through
150 translational control, whereby Ca^{++} influx through NMDAR activity limits protein elongation [18].
151 To test for the role of translation, neurons were treated with anisomycin (10uM), a well-
152 established blocker of protein elongation. Treatment with anisomycin abolished the APV-
153 induced increase in synaptic Cav2.3, suggesting that translation was indeed required for the
154 increase of synaptic R-VGCCs triggered by the NMDAR blockade (**Fig. 1g**).

155 This study reports that neuronal activity rapidly controls levels of R-VGCCs in the synapse
156 through excitatory synaptic transmission, synaptic NMDAR signalling and translation. This
157 regulation is likely to be indirect, given that translation rate of Cav2.3 itself has been shown to
158 be activity-independent [19]. Nevertheless, spatial proximity between NMDARs and R-VGCCs
159 at the postsynaptic compartment [13,15] would suggest the involvement of local processes. In
160 agreement with this notion, the timescale of the observed coupling between NMDARs and R-
161 VGCCs (within 1h) is considerably faster than the previously reported slow (24-48h)
162 mechanisms of homeostatic plasticity regulating presynaptic Cav2-containing VGCCs
163 [10,16,20]. In contrast, P/Q and N-VGCCs are primarily presynaptic, and the slower timescale of

164 their regulation by neuronal activity likely reflects involvement of other mechanisms, which may
165 operate either presynaptically or across the cell.

166 Upregulation of synaptic R-VGCCs by both blockade of excitatory NMDAR receptors as well as
167 blockade of inhibitory GABA receptors may seem paradoxical (**Fig. 1b**), given that blocking of
168 inhibitory neurotransmission by GABA receptor antagonists immediately increases neuronal
169 firing [21]. However, this effect is consistent with blockade of GABAergic transmission triggering
170 activity-induced reduction in synaptic NMDAR content [22,23]. Therefore, it may be concluded
171 that three different ways of downregulation of synaptic NMDAR function – due to either
172 blockade of neuronal firing, or homeostatic reduction in synaptic NMDAR levels through
173 increased neuronal firing, or simply by direct pharmacological blockade of synaptic NMDARs –
174 all lead to the same outcome, i.e. upregulation in synaptic R-VGCCs.

175 Given the spatial constraints dominating local signalling at the synapse, restriction of local Ca⁺⁺
176 signalling through the feedback mechanism reported here is likely to be a key factor allowing for
177 co-existence of multiple signalling pathways within the synapse through tuning synaptic Ca⁺⁺
178 signalling to neuronal activity [13]. Considering the major role of synaptic Ca⁺⁺ signalling in
179 neuronal development, plasticity, and pathology, observations reported here will warrant deeper
180 investigation of the relationship between local NMDAR and VGCC signalling. This will be of
181 particular interest in functionally relevant contexts implicating R-type VGCCs, e.g. neuronal
182 development [24], physiologically validated forms of synaptic plasticity, and neuronal pathology
183 [11,25,26].

184 Conflict of Interest

185 None.

186 Data availability statement

187 The data that support the findings of this study are available from the corresponding author
188 upon reasonable request.

189 References

- 190 1 Südhof TC (2012) Calcium control of neurotransmitter release. *Cold Spring Harb Perspect*
191 *Biol* **4**, a011353.
- 192 2 Südhof TC (2012) The presynaptic active zone. *Neuron* **75**, 11–25.
- 193 3 Higley MJ & Sabatini BL (2012) Calcium signaling in dendritic spines. *Cold Spring Harb*
194 *Perspect Biol* **4**, a005686.

- 195 4 Catterall WA (2011) Voltage-gated calcium channels. *Cold Spring Harb Perspect Biol* **3**,
196 a003947.
- 197 5 Collingridge GL, Peineau S, Howland JG & Wang YT (2010) Long-term depression in the
198 CNS. *Nat Rev Neurosci* **11**, 459–73.
- 199 6 Vyklicky V, Korinek M, Smejkalova T, Balik A, Krausova B, Kaniakova M, Lichnerova K, Cerny
200 J, Krusek J, Dittert I, Horak M & Vyklicky L (2014) Structure, function, and pharmacology of
201 NMDA receptor channels. *Physiol Res* **63 Suppl 1**, S191-203.
- 202 7 Holderith N, Lorincz A, Katona G, Rózsa B, Kulik A, Watanabe M & Nusser Z (2012) Release
203 probability of hippocampal glutamatergic terminals scales with the size of the active zone.
204 *Nat Neurosci* **15**, 988–97.
- 205 8 Nakamura Y, Harada H, Kamasawa N, Matsui K, Rothman JS, Shigemoto R, Silver RA,
206 DiGregorio DA & Takahashi T (2014) Nanoscale Distribution of Presynaptic Ca²⁺
207 Channels and Its Impact on Vesicular Release during Development. *Neuron* **85**, 145–58.
- 208 9 Indriati DW, Kamasawa N, Matsui K, Meredith AL, Watanabe M & Shigemoto R (2013)
209 Quantitative localization of Cav2.1 (P/Q-type) voltage-dependent calcium channels in
210 Purkinje cells: somatodendritic gradient and distinct somatic coclustering with calcium-
211 activated potassium channels. *J Neurosci* **33**, 3668–78.
- 212 10 Glebov OO, Jackson RE, Winterflood CM, Owen DM, Barker EA, Doherty P, Ewers H &
213 Burrone J (2017) Nanoscale Structural Plasticity of the Active Zone Matrix Modulates
214 Presynaptic Function. *Cell Rep* **18**, 2715–2728.
- 215 11 Wormuth C, Lundt A, Henseler C, Müller R, Broich K, Papazoglou A & Weiergräber M (2016)
216 Review: Cav2.3 R-type Voltage-Gated Ca²⁺ Channels - Functional Implications in
217 Convulsive and Non-convulsive Seizure Activity. *Open Neurol J* **10**, 99–126.
- 218 12 Parajuli LK, Nakajima C, Kulik A, Matsui K, Schneider T, Shigemoto R & Fukazawa Y (2012)
219 Quantitative Regional and Ultrastructural Localization of the Cav2.3 Subunit of R-type
220 Calcium Channel in Mouse Brain. *J Neurosci* **32**, 13555–13567.
- 221 13 Bloodgood BL & Sabatini BL (2007) Ca²⁺ signaling in dendritic spines. *Curr Opin Neurobiol*
222 **17**, 345–351.
- 223 14 Theis A-K, Rózsa B, Katona G, Schmitz D & Jochenning FW (2018) Voltage Gated Calcium
224 Channel Activation by Backpropagating Action Potentials Downregulates NMDAR
225 Function. *Front Cell Neurosci* **12**, 109.
- 226 15 Bloodgood BL & Sabatini BL (2007) Nonlinear Regulation of Unitary Synaptic Signals by
227 CaV2.3 Voltage-Sensitive Calcium Channels Located in Dendritic Spines. *Neuron* **53**, 249–
228 260.
- 229 16 Lazarevic V, Schöne C, Heine M, Gundelfinger ED & Fejtova A (2011) Extensive remodeling
230 of the presynaptic cytomatrix upon homeostatic adaptation to network activity silencing. *J*
231 *Neurosci* **31**, 10189–200.
- 232 17 Xia P, Chen H -s. V., Zhang D & Lipton SA (2010) Memantine Preferentially Blocks
233 Extrasynaptic over Synaptic NMDA Receptor Currents in Hippocampal Autapses. *J*
234 *Neurosci* **30**, 11246–11250.
- 235 18 Hoeffler CA & Klann E (2009) *NMDA Receptors and Translational Control* CRC Press/Taylor
236 & Francis.
- 237 19 Schanzenbächer CT, Sambandan S, Langer JD & Schuman EM (2016) Nascent Proteome
238 Remodeling following Homeostatic Scaling at Hippocampal Synapses. *Neuron* **92**, 358–
239 371.
- 240 20 Zhao C, Dreosti E & Lagnado L (2011) Homeostatic synaptic plasticity through changes in
241 presynaptic calcium influx. *J Neurosci* **31**, 7492–6.
- 242 21 Wiegert JS, Hofmann F, Bading H & Bengtson CP (2009) A transcription-dependent increase
243 in miniature EPSC frequency accompanies late-phase plasticity in cultured hippocampal
244 neurons. *BMC Neurosci* **10**, 124.
- 245 22 Ehlers MD (2003) Activity level controls postsynaptic composition and signaling via the

- 246 ubiquitin-proteasome system. *Nat Neurosci* **6**, 231–42.
247 23 Watt AJ, Van Rossum MCW, MacLeod KM, Nelson SB & Turrigiano GG (2000) Activity
248 coregulates quantal AMPA and NMDA currents at neocortical synapses. *Neuron* **26**, 659–
249 670.
250 24 Nishiyama M, Togashi K, von Schimmelmann MJ, Lim C-S, Maeda S, Yamashita N,
251 Goshima Y, Ishii S & Hong K (2011) Semaphorin 3A induces Cav2.3 channel-dependent
252 conversion of axons to dendrites. *Nat Cell Biol* **13**, 676–685.
253 25 Weiergraber M, Henry M, Krieger A, Kamp M, Radhakrishnan K, Hescheler J & Schneider T
254 (2006) Altered Seizure Susceptibility in Mice Lacking the Cav2.3 E-type Ca²⁺ Channel.
255 *Epilepsia* **47**, 839–850.
256 26 Yokoyama K, Kurihara T, Saegusa H, Zong S, Makita K & Tanabe T (2004) Blocking the R-
257 type (Cav2.3) Ca²⁺ channel enhanced morphine analgesia and reduced morphine
258 tolerance. *Eur J Neurosci* **20**, 3516–3519.
259
260

261 Figure legends

262

263 **Figure 1. Synaptic NMDAR signalling controls levels of synaptic R-VGCCs.**

264 **a**, cells were treated with 2uM TTX, 50uM gabazine or 15mM KCl for 1h at 37C, fixed and
265 immunostained for PSD95 and Cav2.3. Arrows highlight accumulation of Cav2.3 in PSD95-
266 positive puncta corresponding to the synapses. Scale bar, 20um. **b**, quantification of Cav2.3
267 intensities in PSD-95 positive puncta normalized to PSD95 intensity. ns – not significant,
268 *p<0.05, 1-way ANOVA and Dunnett's post-test, N=15 fields of view from 3 independent
269 experiments. **c**, Cells were treated with 20uM NBQX, 50uM APV or 20uM MK801 for 1h at 37C.
270 Quantification of Cav2.3 intensities in PSD-95 positive puncta normalized to PSD95 intensity. ns
271 – not significant, ***p<0.001, **p<0.01, *p<0.05, 1-way ANOVA and Dunnett's post-test, N=15
272 fields of view from 3 independent experiments. **d**, Cells were treated with 50uM APV for 1h at
273 37C. Quantification of Cav2.3 intensities in Bassoon-positive puncta normalized to Bassoon
274 intensity. **p<0.01, Student's t-test. N=20 fields of view from 4 independent experiments. **e**,
275 cells were treated with 50uM MK801 for 1h at 37C. Quantification of Cav2.3 intensities in
276 Bassoon-positive puncta normalized to Bassoon intensity. ****p<0.0001, Mann-Whitney test.
277 N=20 fields of view from 4 independent experiments. **f**, Cells were treated with varying
278 concentrations of memantine for 1h at 37C. Quantification of Cav2.3 intensities in Bassoon-
279 positive puncta normalized to Bassoon intensity. ***p<0.001, 1-way ANOVA and Student's t-
280 test. N=15 fields of view from 3 independent experiments. **g**, Cells were treated with 50uM APV
281 and 10uM Anisomycin for 1h at 37C. Quantification of Cav2.3 intensities in Bassoon-positive

282 puncta normalized to Bassoon intensity. ** $p < 0.01$, * $p < 0.05$, ns not significant, 1-way ANOVA
283 and Student's t-test. N=20 fields of view from 4 independent experiments.

284

285 **Figure S1. Extended experimental data.** **a**, quantification of PSD-95 intensities in PSD-95
286 positive puncta. ns – not significant, 1-way ANOVA and Dunnett's post-test, N=15 fields of view
287 from 3 independent experiments. **b**, Accumulation of Cav2.3 labelling in the soma of neurons
288 following APV treatment. * $p < 0.05$, Mann-Whitney test, N=15 cells from 3 independent
289 experiments. **c**, Neurons were immunostained for Cav2.3 and Bassoon. Arrows highlight
290 accumulation of Cav2.3 signal in Bassoon-positive puncta. Scale bar, 20 μ m. **d**, ditto for Cav2.2.
291 **e**, ditto for Cav2.2. **f**, Lack of enrichment of Cav2.1 in Bassoon-positive areas following APV
292 treatment. ns - not significant, Mann-Whitney test. N=15 fields of view from 3 independent
293 experiments. **g**, Lack of enrichment of Cav2.2 in Bassoon-positive areas following APV
294 treatment. ns - not significant, Mann-Whitney test. N=20 fields of view from 4 independent
295 experiments.

Figure 1

bioRxiv preprint doi: <https://doi.org/10.1101/2020.11.25.399212>; this version posted November 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.




Figure S1

bioRxiv preprint doi: <https://doi.org/10.1101/2020.11.25.399212>; this version posted November 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




Figure S1

bioRxiv preprint doi: <https://doi.org/10.1101/2020.11.25.399212>; this version posted November 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

